ArticleBlood cancer journal2024

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.

Niels W C J van de Donk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.